Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction

Patricia Pellikka, T. Behrenbeck, M. S. Verani, J. J. Mahmarian, F. J T Wackers, Raymond J Gibbons

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Resting tomographic myocardial perfusion images using technetium-99m-hexakis-2-methylpropyl-isonitrile (Tc-Sestamibi) were obtained in 25 patients during their first myocardial infarction. Tc-Sestamibi was injected intravenously before acute reperfusion therapy, and repeated twice, at 18-48 hr, and at 6 to 14 days. Reperfusion was successful in 19 patients. In the patients with successful reperfusion, there was a mean decrease in the amount of hypoperfused myocardium between the initial and second studies (-9% ± 12%, p = 0.004) and a further decrease between the second and final studies (-10% ± 12%, p = 0.002). Nine of these 19 patients (47%) had evidence of significant improvement at the time of the second study. In six patients, significant improvement was not evident until the final study. Although tomographic imaging with Tc-Sestamibi following reperfusion therapy may show improvement in perfusion at 18-48 hr, the full extent of improvement is usually not evident until later.

Original languageEnglish (US)
Pages (from-to)1269-1275
Number of pages7
JournalJournal of Nuclear Medicine
Volume31
Issue number8
StatePublished - 1990

Fingerprint

Technetium
Reperfusion
Perfusion
Myocardial Infarction
Therapeutics
Myocardium

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction. / Pellikka, Patricia; Behrenbeck, T.; Verani, M. S.; Mahmarian, J. J.; Wackers, F. J T; Gibbons, Raymond J.

In: Journal of Nuclear Medicine, Vol. 31, No. 8, 1990, p. 1269-1275.

Research output: Contribution to journalArticle

@article{f03ab1aa5dbb44a0a1b4777e2bc8e737,
title = "Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction",
abstract = "Resting tomographic myocardial perfusion images using technetium-99m-hexakis-2-methylpropyl-isonitrile (Tc-Sestamibi) were obtained in 25 patients during their first myocardial infarction. Tc-Sestamibi was injected intravenously before acute reperfusion therapy, and repeated twice, at 18-48 hr, and at 6 to 14 days. Reperfusion was successful in 19 patients. In the patients with successful reperfusion, there was a mean decrease in the amount of hypoperfused myocardium between the initial and second studies (-9{\%} ± 12{\%}, p = 0.004) and a further decrease between the second and final studies (-10{\%} ± 12{\%}, p = 0.002). Nine of these 19 patients (47{\%}) had evidence of significant improvement at the time of the second study. In six patients, significant improvement was not evident until the final study. Although tomographic imaging with Tc-Sestamibi following reperfusion therapy may show improvement in perfusion at 18-48 hr, the full extent of improvement is usually not evident until later.",
author = "Patricia Pellikka and T. Behrenbeck and Verani, {M. S.} and Mahmarian, {J. J.} and Wackers, {F. J T} and Gibbons, {Raymond J}",
year = "1990",
language = "English (US)",
volume = "31",
pages = "1269--1275",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "8",

}

TY - JOUR

T1 - Serial changes in myocardial perfusion using tomographic technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile imaging following reperfusion therapy of myocardial infarction

AU - Pellikka, Patricia

AU - Behrenbeck, T.

AU - Verani, M. S.

AU - Mahmarian, J. J.

AU - Wackers, F. J T

AU - Gibbons, Raymond J

PY - 1990

Y1 - 1990

N2 - Resting tomographic myocardial perfusion images using technetium-99m-hexakis-2-methylpropyl-isonitrile (Tc-Sestamibi) were obtained in 25 patients during their first myocardial infarction. Tc-Sestamibi was injected intravenously before acute reperfusion therapy, and repeated twice, at 18-48 hr, and at 6 to 14 days. Reperfusion was successful in 19 patients. In the patients with successful reperfusion, there was a mean decrease in the amount of hypoperfused myocardium between the initial and second studies (-9% ± 12%, p = 0.004) and a further decrease between the second and final studies (-10% ± 12%, p = 0.002). Nine of these 19 patients (47%) had evidence of significant improvement at the time of the second study. In six patients, significant improvement was not evident until the final study. Although tomographic imaging with Tc-Sestamibi following reperfusion therapy may show improvement in perfusion at 18-48 hr, the full extent of improvement is usually not evident until later.

AB - Resting tomographic myocardial perfusion images using technetium-99m-hexakis-2-methylpropyl-isonitrile (Tc-Sestamibi) were obtained in 25 patients during their first myocardial infarction. Tc-Sestamibi was injected intravenously before acute reperfusion therapy, and repeated twice, at 18-48 hr, and at 6 to 14 days. Reperfusion was successful in 19 patients. In the patients with successful reperfusion, there was a mean decrease in the amount of hypoperfused myocardium between the initial and second studies (-9% ± 12%, p = 0.004) and a further decrease between the second and final studies (-10% ± 12%, p = 0.002). Nine of these 19 patients (47%) had evidence of significant improvement at the time of the second study. In six patients, significant improvement was not evident until the final study. Although tomographic imaging with Tc-Sestamibi following reperfusion therapy may show improvement in perfusion at 18-48 hr, the full extent of improvement is usually not evident until later.

UR - http://www.scopus.com/inward/record.url?scp=0025168359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025168359&partnerID=8YFLogxK

M3 - Article

C2 - 2143527

AN - SCOPUS:0025168359

VL - 31

SP - 1269

EP - 1275

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 8

ER -